5-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-2,3-dihydroindole-1-carboxamide GTPL7584 SCHEMBL12972358
BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently was shown to inhibit JAK2 activity (IC50= 8nM ~ 29nM in murine models). The Type II JAK2 inhibitor NVP-BBT594 also displayed potent inhibition of HCV activity (EC50< 1.5 mM). BBT594 impairs GDNF-RET signaling, a promising therapeutic target to enhance the sensitivity to aromatase inhibitor (AI) treatment and revert AI resistance in ER+ breast cancer cells. It also impairs GDNF-dependent growth of MCF7-LTED cells. #
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View